Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Operations (2022 - 2025)

Entrada Therapeutics has reported Cash from Operations over the past 4 years, most recently at 32203000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 32203000.0 for Q4 2025, down 1.89% from a year ago — trailing twelve months through Dec 2025 was 128512000.0 (down 209.24% YoY), and the annual figure for FY2025 was 128512000.0, down 209.24%.
  • Cash from Operations for Q4 2025 was 32203000.0 at Entrada Therapeutics, down from 28313000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for TRDA hit a ceiling of 203399000.0 in Q1 2023 and a floor of 38507000.0 in Q1 2025.
  • Median Cash from Operations over the past 4 years was 26411500.0 (2022), compared with a mean of 7753250.0.
  • Biggest five-year swings in Cash from Operations: skyrocketed 1068.98% in 2023 and later tumbled 687.57% in 2024.
  • Entrada Therapeutics' Cash from Operations stood at 27304000.0 in 2022, then soared by 85.3% to 4013000.0 in 2023, then tumbled by 687.57% to 31605000.0 in 2024, then dropped by 1.89% to 32203000.0 in 2025.
  • The last three reported values for Cash from Operations were 32203000.0 (Q4 2025), 28313000.0 (Q3 2025), and 29489000.0 (Q2 2025) per Business Quant data.